Protein Markers Predict Risk of Melanoma Recurrence

December 3, 2009

( -- A new prognostic tool that can determine the risk of recurrence in melanoma patients has been developed by researchers at Yale Cancer Center. The technology, based on five proteins expressed in melanoma tissue, can classify patients into a low-risk group, with 10% chance of recurrence at eight years, or a high-risk group that has a 40% probability of recurrence within that time. The study appears in the December 1 issue of the Journal of Clinical Oncology.

Twenty to sixty percent of patients with stage II will later be diagnosed with metastatic melanoma due to a recurrence of their disease. This new tool will help to identify patients who are at increased risk for recurrence so that they can be more carefully monitored.

“This test has the potential to really help melanoma patients and their clinicians decide how to manage their disease,” said David L. Rimm, M.D., Ph.D., lead author and professor of pathology at Yale School of Medicine.

The Yale Cancer Center research team analyzed protein expression from a historic group of tumor samples from patients taken from 1959 to 1994 and then tested it on an independent group of patient samples from surgery performed by Dr. Stephan Ariyan, clinical professor of surgery and director of the Yale Cancer Center Melanoma Program.

The prognostic tool is based on the AQUA™ system, a technology developed at Yale School of Medicine by Rimm and Robert L. Camp, M.D. AQUA automatically measures and localizes specific variations in protein expression within tissue with a high level of precision. The multi-tissue proteomic analysis system combines fluorescence-based imaging with automated microscopy and high-throughput tissue microarray technologies.

HistoRx, a biotechnology company based in New Haven, has an exclusive license for the AQUA™system.

More information: J Clin Oncol. 2009 Dec 1;27(34):5772-80.

Provided by Yale University (news : web)

Related Stories

Recommended for you

Insights on how SHARPIN promotes cancer progression

December 11, 2017
Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex ...

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

Scientists discover possible master switch for programming cancer immunotherapy

December 11, 2017
During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells ...

Liver cancer: Lipid synthesis promotes tumor formation

December 11, 2017
Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the ...

Use of chemotherapy for early stage breast cancer declines, study says

December 11, 2017
A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.